Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was a randomized, open, parallel, controlled, multi-center, interventional, cross-sectional study to evaluate the detection rate of Psoriatic arthritis (PsA) in Korean moderate to severe Psoriasis (PsO) patients with or without the Early arthritis for psoriatic patients (EARP) screening.
All procedures for each patient were performed for one day. If an additional time was required depending on the circumstances of the institution and so on, the data specified in this study protocol were recommended to be collected as soon as possible. After the participants enrolled in this study, they were assessed whether they met the inclusion/exclusion criteria. In terms of the severity of PsO, it was assessed with the Psoriasis Area and Severity Index (PASI) and if the score of 10 or higher was defined as moderate to severe PsO. A total 368 eligible participants were randomized 1:1 ratio into the EARP group and the Routine practice group.
For the EARP group, the investigator asked the participants about the EARP questionnaire consisting of 10 questions. When the EARP score >= 3, the participants were suspected for having potential PsA. For Routine practice group, the investigator selected the participants suspected of PsA in consideration of the various clinical characteristics of the participants.
After the completion of EARP questionnaire evaluation and the investigator's judgement as per routine practice in each group, all the participants were evaluated using Classification criteria for psoriatic arthritis (CASPAR). According to the CASPAR, participants having inflammatory articular disease with 3 or more points from the CASPAR were diagnosed as PsA, and the detection rate of PsA in each group was evaluated and compared.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| EARP group | Other | For the EARP group, the investigator provided this questionnaire to participants, who filled out it based on their symptoms. Afterwards, the investigator calculated the total score of the questionnaire answered by the participant, and further evaluated the participants using the CASPAR. |
|
| Routine practice group | Active Comparator | In the control group, PsA risk was assessed in moderate to severe PsO patients as per routine practice without using the EARP screening. After the completion of PsA risk assessment via routine practice according to the investigator's judgement, the participants were further evaluated using the CASPAR. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Routine practice group | Diagnostic Test | Routine practice group |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Detection Rate of Psoriatic Arthritis (PsA) | After the completion of EARP questionnaire evaluation and the investigator's judgement as per routine practice in each group, all the participants were evaluated using Classification criteria for psoriatic arthritis (CASPAR). According to the CASPAR, participants having inflammatory articular disease with 3 or more points from the CASPAR were diagnosed as PsA, and the detection rate of PsA in each group was evaluated and compared. The detection rate of Psoriatic Arthritis (PsA) amongst moderate to severe Psoriasis (PsO) patients between the EARP group and the Routine practice groups was defined as the percentage of patients with true positive results divided by all patients in each EARP and Routine practice group. The true positive results were defined as patients with a classification criteria for psoriatic arthritis (CASPAR) score >= 3 among EARP >= 3 for the EARP group and among those suspected of PsA by investigator's judgement for the Routine Practice group. | Visit 1 (Day 1) |
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity, Specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) Between EARP Questionnaire (EARP Group) and the Investigator's Judgement (Routine Practice Group) | Sensitivity was summarized with the number and percentage of patients who have true positive (TP) among those who have true positive (TP) and false negative (FN). Specificity was summarized with the number and percentage of patients who have true negative (TN) among those who have true negative (TN) and false positive (FP). Positive predictive value (PPV) was summarized with the number and percentage of patients who have true positive (TP) among those who have true positive (TP) and false positive (FP). Negative predictive value (NPV) was summarized with the number and percentage of patients who have true negative (TN) among those who have true negative (TN) and false negative (FN). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients who have formal pre-existing diagnosis of PsA
Patients who have ever received treatment with biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Patients who currently receive systemic glucocorticoids
Patients who currently receive opioid analgesics
Patients who has other known pre-existing dermatological or rheumatological diseases:
Female patients who are pregnant
Patients who are participating in other interventional clinical trials
Patients who have already had PsA screening via screening questionnaires or imaging
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | Bundang Gu | Gyeonggi-do | 13620 | South Korea | ||
| Novartis Investigative Site |
Not provided
| Label | URL |
|---|---|
| A Plain Language Trial Summary is available on www.novctrd.com | View source |
Not provided
Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Not provided
Not provided
Not provided
Not provided
Participants who met all inclusion criteria and none of the exclusion criteria were centrally, randomly allocated with a 1:1 ratio to either the EARP group or the Routine practice group using an Interactive Web Response System (IWRS).
This study was conducted at 15 centers in the Republic of Korea.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | EARP Group | For the EARP group, the investigator provided this questionnaire to participants, who filled out it based on their symptoms. Afterwards, the investigator calculated the total score of the questionnaire answered by the participant, and further evaluated the participants using the CASPAR. |
| FG001 |
| Title | Milestones | Reasons Not Completed | ||||
|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Mar 29, 2022 | May 24, 2024 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| EARP group |
| Diagnostic Test |
EARP group |
|
| Visit 1 (Day 1) |
| Age Characteristics by Participants With or Without PsA | Age characteristics between patients with PsA and without PsA were analyzed and compared. | Visit 1 (Day 1) |
| Gender Characteristics by Participants With or Without PsA | Gender characteristics between patients with PsA and without PsA were analyzed and compared. | Visit 1 (Day 1) |
| Body Mass Index (BMI) Characteristics by Participants With or Without PsA | Body Mass Index (BMI) characteristics between patients with PsA and without PsA were analyzed and compared. | Visit 1 (Day 1) |
| Drinking and Smoking History Characteristics by Participants With or Without PsA | Drinking and smoking history characteristics between patients with PsA and without PsA were analyzed and compared. | Visit 1 (Day 1) |
| Duration of Psoriasis (PsO) Characteristics by Participants With or Without PsA | Duration of Psoriasis (PsO) characteristics between patients with PsA and without PsA were analyzed and compared. | Visit 1 (Day 1) |
| Family History of Psoriasis (PsO) and Psoriatic Arthritis (PsA) Characteristics by Participants With or Without PsA | Family history of psoriasis (PsO) and psoriatic arthritis (PsA) characteristics between patients with PsA and without PsA were analyzed and compared. | Visit 1 (Day 1) |
| Psoriasis Area and Severity Index (PASI) Score Characteristics by Participants With or Without PsA | PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease). The body is divided into four sections (head (H) (10% of a person's skin); arms (A) (20%); trunk (T) (30%); legs (L) (40%)). Each of these areas is scored by itself, and then the four scores are combined into the final PASI. For each section, the percent of area of skin involved, is estimated and then transformed into a grade from 0 (0% of involved area) to 6 (90-100% of involved area). Within each area, the severity is estimated by three clinical signs: erythema (redness), induration (thickness) and desquamation (scaling). Severity parameters are measured on a scale of 0 (none) to 4 (maximum). The sum of all three severity parameters is then calculated for each section of skin, multiplied by the area score for that area and multiplied by weight of respective section (0.1 for head, 0.2 for arms, 0.3 for body and 0.4 for legs). | Visit 1 (Day 1) |
| The Status of Hard-to-treat Area Involvement and Musculoskeletal Symptoms Characteristics by Participants With or Without PsA | The presence or absence of hard-to-treat area involvement (scalp, palmoplantar, nails) and presence or absence of musculoskeletal symptoms between patients with PsA and without PsA were analyzed and compared. | Visit 1 (Day 1) |
| Nail Psoriasis Severity Index (NAPSI) Score Characteristics by Participants With or Without PsA | The Nail Psoriasis Severity Index (NAPSI) score is used to measure psoriasis of the nails. Each nail is divided into 4 equal and symmetrical quadrants to properly assess nail matrix and nail bed changes. Each nail is given a score for nail bed PsO and nail matrix PsO ranging from 0 (none) to 4 (present in 4/4 nail) depending on the presence of any of the features of nail PsO in that quadrant. A total score per nail is 0-8, and the range of the total scores from all nails is 0-160 (toenails are included). | Visit 1 (Day 1) |
| SJC66/TJC68 Total Joint Count Characteristics by Participants With or Without PsA | 66 swollen and 68 tender joints are assessed (the hips are not assessed for swelling). The joint count is scored as a sum of the tender joints and a sum of the swollen joints. SJC66: swollen joint count in 66 joints; TJC68: tender joint count in 66 joints. | Visit 1 (Day 1) |
| Solicited Medical History by Participants With or Without PsA | The presence or absence of co-morbidities (heart diseases, stroke, diabetes, hyperlipidemia, hypertension and fatty liver)) between patients with PsA and without PsA were analyzed and compared. | Visit 1 (Day 1) |
| Percentage of Participants With PsO Related Treatment Other Than Medications by Participants With or Without PsA | The presence or absence of PsO related treatment other than medications (UV light therapy, Psoralen with ultraviolet A (PUVA), Phototherapy and Laser therapy and Naturopathy) between patients with PsA and without PsA was analyzed and compared. | Visit 1 (Day 1) |
| Seongnam-si |
| Gyeonggi-do |
| 463-712 |
| South Korea |
| Novartis Investigative Site | Seoul | Korea | 02447 | South Korea |
| Novartis Investigative Site | Seoul | Korea | 08308 | South Korea |
| Novartis Investigative Site | Bucheon-si | 14647 | South Korea |
| Novartis Investigative Site | Busan | 48108 | South Korea |
| Novartis Investigative Site | Busan | 49241 | South Korea |
| Novartis Investigative Site | Gwangju | 501171 | South Korea |
| Novartis Investigative Site | Seoul | 03080 | South Korea |
| Novartis Investigative Site | Seoul | 03722 | South Korea |
| Novartis Investigative Site | Seoul | 04763 | South Korea |
| Novartis Investigative Site | Seoul | 05030 | South Korea |
| Novartis Investigative Site | Seoul | 07441 | South Korea |
| Novartis Investigative Site | Seoul | 110-746 | South Korea |
| Novartis Investigative Site | Taegu | 41944 | South Korea |
| Routine Practice Group |
In the control group, PsA risk was assessed in moderate to severe PsO patients as per routine practice without using the EARP screening. After the completion of PsA risk assessment via routine practice according to the investigator's judgement, the participants were further evaluated using the CASPAR. |
|
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | EARP Group | For the EARP group, the investigator provided this questionnaire to participants, who filled out it based on their symptoms. Afterwards, the investigator calculated the total score of the questionnaire answered by the participant, and further evaluated the participants using the CASPAR. |
| BG001 | Routine Practice Group | In the control group, PsA risk was assessed in moderate to severe PsO patients as per routine practice without using the EARP screening. After the completion of PsA risk assessment via routine practice according to the investigator's judgement, the participants were further evaluated using the CASPAR. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants |
| ||||||||||||||||
| Height | Mean | Standard Deviation | cm |
| |||||||||||||||
| Weight | Mean | Standard Deviation | kg |
| |||||||||||||||
| Body Mass Index (BMI) | Mean | Standard Deviation | kg/m^2 |
| |||||||||||||||
| Drinking history | Count of Participants | Participants |
| ||||||||||||||||
| Smoking history | Count of Participants | Participants |
| ||||||||||||||||
| Duration of Psoriasis (PsO) | Mean | Standard Deviation | months |
| |||||||||||||||
| Psoriasis Area and Severity Index (PASI) score | PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease). The body is divided into four sections (head (H) (10% of a person's skin); arms (A) (20%); trunk (T) (30%); legs (L) (40%)). Each of these areas is scored by itself, and then the four scores are combined into the final PASI. | Mean | Standard Deviation | Unit on a scale |
| ||||||||||||||
| Psoriasis Area and Severity Index (PASI) category | PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease). The body is divided into four sections (head (H) (10% of a person's skin); arms (A) (20%); trunk (T) (30%); legs (L) (40%)). Each of these areas is scored by itself, and then the four scores are combined into the final PASI. | Count of Participants | Participants |
| |||||||||||||||
| Psoriasis (PsO) family history | Count of Participants | Participants |
| ||||||||||||||||
| Psoriatic Arthritis (PsA) family history | Count of Participants | Participants |
| ||||||||||||||||
| Presence or absence of hard-to-treat area involvement (scalp, palmoplantar, nails) | Count of Participants | Participants |
| ||||||||||||||||
| Presence or absence of musculoskeletal symptoms | Count of Participants | Participants |
| ||||||||||||||||
| Total Nail Psoriasis Severity Index (NAPSI) score | The Nail Psoriasis Severity Index (NAPSI) score is used to measure psoriasis of the nails. Each nail is divided into 4 equal and symmetrical quadrants to properly assess nail matrix and nail bed changes. Each nail is given a score for nail bed PsO and nail matrix PsO ranging from 0 (none) to 4 (present in 4/4 nail) depending on the presence of any of the features of nail PsO in that quadrant. A total score per nail is 0-8, and the range of the total scores from all nails is 0-160 (toenails are included). | Mean | Standard Deviation | Unit on a scale |
| ||||||||||||||
| SJC66/TJC68 total joint count | 66 swollen and 68 tender joints are assessed (the hips are not assessed for swelling). The joint count is scored as a sum of the tender joints and a sum of the swollen joints. SJC66: swollen joint count in 66 joints; TJC68: tender joint count in 66 joints. | Mean | Standard Deviation | Joint count |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Detection Rate of Psoriatic Arthritis (PsA) | After the completion of EARP questionnaire evaluation and the investigator's judgement as per routine practice in each group, all the participants were evaluated using Classification criteria for psoriatic arthritis (CASPAR). According to the CASPAR, participants having inflammatory articular disease with 3 or more points from the CASPAR were diagnosed as PsA, and the detection rate of PsA in each group was evaluated and compared. The detection rate of Psoriatic Arthritis (PsA) amongst moderate to severe Psoriasis (PsO) patients between the EARP group and the Routine practice groups was defined as the percentage of patients with true positive results divided by all patients in each EARP and Routine practice group. The true positive results were defined as patients with a classification criteria for psoriatic arthritis (CASPAR) score >= 3 among EARP >= 3 for the EARP group and among those suspected of PsA by investigator's judgement for the Routine Practice group. | Full Analysis Set (FAS) | Posted | Count of Participants | Participants | Visit 1 (Day 1) |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Sensitivity, Specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) Between EARP Questionnaire (EARP Group) and the Investigator's Judgement (Routine Practice Group) | Sensitivity was summarized with the number and percentage of patients who have true positive (TP) among those who have true positive (TP) and false negative (FN). Specificity was summarized with the number and percentage of patients who have true negative (TN) among those who have true negative (TN) and false positive (FP). Positive predictive value (PPV) was summarized with the number and percentage of patients who have true positive (TP) among those who have true positive (TP) and false positive (FP). Negative predictive value (NPV) was summarized with the number and percentage of patients who have true negative (TN) among those who have true negative (TN) and false negative (FN). | Full Analysis Set (FAS) | Posted | Count of Participants | Participants | Visit 1 (Day 1) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Age Characteristics by Participants With or Without PsA | Age characteristics between patients with PsA and without PsA were analyzed and compared. | Full Analysis Set (FAS) | Posted | Mean | Standard Deviation | Years | Visit 1 (Day 1) |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Gender Characteristics by Participants With or Without PsA | Gender characteristics between patients with PsA and without PsA were analyzed and compared. | Full Analysis Set (FAS) | Posted | Count of Participants | Participants | Visit 1 (Day 1) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Body Mass Index (BMI) Characteristics by Participants With or Without PsA | Body Mass Index (BMI) characteristics between patients with PsA and without PsA were analyzed and compared. | Full Analysis Set (FAS) | Posted | Mean | Standard Deviation | kg/m^2 | Visit 1 (Day 1) |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Drinking and Smoking History Characteristics by Participants With or Without PsA | Drinking and smoking history characteristics between patients with PsA and without PsA were analyzed and compared. | Full Analysis Set (FAS) | Posted | Count of Participants | Participants | Visit 1 (Day 1) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Duration of Psoriasis (PsO) Characteristics by Participants With or Without PsA | Duration of Psoriasis (PsO) characteristics between patients with PsA and without PsA were analyzed and compared. | Full Analysis Set (FAS) | Posted | Mean | Standard Deviation | months | Visit 1 (Day 1) |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Family History of Psoriasis (PsO) and Psoriatic Arthritis (PsA) Characteristics by Participants With or Without PsA | Family history of psoriasis (PsO) and psoriatic arthritis (PsA) characteristics between patients with PsA and without PsA were analyzed and compared. | Full Analysis Set (FAS) | Posted | Count of Participants | Participants | Visit 1 (Day 1) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Psoriasis Area and Severity Index (PASI) Score Characteristics by Participants With or Without PsA | PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease). The body is divided into four sections (head (H) (10% of a person's skin); arms (A) (20%); trunk (T) (30%); legs (L) (40%)). Each of these areas is scored by itself, and then the four scores are combined into the final PASI. For each section, the percent of area of skin involved, is estimated and then transformed into a grade from 0 (0% of involved area) to 6 (90-100% of involved area). Within each area, the severity is estimated by three clinical signs: erythema (redness), induration (thickness) and desquamation (scaling). Severity parameters are measured on a scale of 0 (none) to 4 (maximum). The sum of all three severity parameters is then calculated for each section of skin, multiplied by the area score for that area and multiplied by weight of respective section (0.1 for head, 0.2 for arms, 0.3 for body and 0.4 for legs). | Full Analysis Set (FAS) | Posted | Mean | Standard Deviation | Unit on a scale | Visit 1 (Day 1) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | The Status of Hard-to-treat Area Involvement and Musculoskeletal Symptoms Characteristics by Participants With or Without PsA | The presence or absence of hard-to-treat area involvement (scalp, palmoplantar, nails) and presence or absence of musculoskeletal symptoms between patients with PsA and without PsA were analyzed and compared. | Full Analysis Set (FAS) | Posted | Count of Participants | Participants | Visit 1 (Day 1) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Nail Psoriasis Severity Index (NAPSI) Score Characteristics by Participants With or Without PsA | The Nail Psoriasis Severity Index (NAPSI) score is used to measure psoriasis of the nails. Each nail is divided into 4 equal and symmetrical quadrants to properly assess nail matrix and nail bed changes. Each nail is given a score for nail bed PsO and nail matrix PsO ranging from 0 (none) to 4 (present in 4/4 nail) depending on the presence of any of the features of nail PsO in that quadrant. A total score per nail is 0-8, and the range of the total scores from all nails is 0-160 (toenails are included). | Full Analysis Set (FAS) | Posted | Mean | Standard Deviation | Unit on a scale | Visit 1 (Day 1) |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | SJC66/TJC68 Total Joint Count Characteristics by Participants With or Without PsA | 66 swollen and 68 tender joints are assessed (the hips are not assessed for swelling). The joint count is scored as a sum of the tender joints and a sum of the swollen joints. SJC66: swollen joint count in 66 joints; TJC68: tender joint count in 66 joints. | Full Analysis Set (FAS) | Posted | Mean | Standard Deviation | Joint count | Visit 1 (Day 1) |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Solicited Medical History by Participants With or Without PsA | The presence or absence of co-morbidities (heart diseases, stroke, diabetes, hyperlipidemia, hypertension and fatty liver)) between patients with PsA and without PsA were analyzed and compared. | Full Analysis Set (FAS) | Posted | Count of Participants | Participants | Visit 1 (Day 1) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With PsO Related Treatment Other Than Medications by Participants With or Without PsA | The presence or absence of PsO related treatment other than medications (UV light therapy, Psoralen with ultraviolet A (PUVA), Phototherapy and Laser therapy and Naturopathy) between patients with PsA and without PsA was analyzed and compared. | Full Analysis Set (FAS). Only participants with PsO related treatment other than medications included. | Posted | Count of Participants | Participants | Visit 1 (Day 1) |
|
|
Not provided
Safety evaluation was not applicable as no drug was involved.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | EARP Group | For the EARP group, the investigator provided this questionnaire to participants, who filled out it based on their symptoms. Afterwards, the investigator calculated the total score of the questionnaire answered by the participant, and further evaluated the participants using the CASPAR. | 0 | 0 | 0 | 0 | 0 | 0 |
| EG001 | Routine Practice Group | In the control group, PsA risk was assessed in moderate to severe PsO patients as per routine practice without using the EARP screening. After the completion of PsA risk assessment via routine practice according to the investigator's judgement, the participants were further evaluated using the CASPAR. | 0 | 0 | 0 | 0 | 0 | 0 |
Not provided
Not provided
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Novartis Pharmaceuticals | 1 862 778 8300 | Novartis.email@Novartis.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jun 15, 2023 | May 24, 2024 | SAP_001.pdf |
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| D015535 | Arthritis, Psoriatic |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D025242 | Spondylarthropathies |
| D025241 | Spondylarthritis |
| D013166 | Spondylitis |
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
Not provided
Not provided
| Male |
|
| Past |
|
| Never |
|
| Past |
|
| Never |
|
| 12 to <14 |
|
| 14 to <16 |
|
| 16 to <18 |
|
| 18 to <20 |
|
| >= 20 |
|
| No |
|
| No |
|
| No |
|
| No |
|
| NAPSI score of right hand |
|
| NAPSI score of left foot |
|
| NAPSI score of right foot |
|
| Total NAPSI score |
|
| TJC68 joint count |
|
| SJC66/TJC68 total joint count |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
|
|
|
|
|
|
|
|
| Never |
|
| Never |
|
| Never |
|
| Never |
|
| Never |
|
| Never |
|